October 6-7, 2022
Milan, Italy - Cloisters of San Barnaba
Chairs:
Pietro Lampertico and Heiner Wedemeyer
In case of non-receipt of the activation email click here
Welcome by Chairs
P. Lampertico and H. Wedemeyer
The HDV virus: the challenge
S. Urban
Pathogenesis of HDV: new insights
J. Lucifora
Immunology of HDV in untreated and treated patients
H. Kefalakes
Epidemiology of HDV: from low to high endemic countries
S. Hamid
Epidemiology of HDV in North America: a forgotten disease?
N. Reau
Diagnosis of HDV: clinical virology and new HBV biomarkers
M. Brunetto
From HDV discovery to perspectives of cure
M. Rizzetto
Non-invasive markers of fibrosis in CHD: pros and cons
L. Castera
Natural history of untreated HDV patients: always a progressive disease?
S. Aleman
Endpoints of HDV therapy
M. Buti
Peginterferon therapy: effectiveness, predictors, and long-term outcomes
T. Asselah
Bulevirtide with or without peginterferon alfa: clinical trials
H. Wedemeyer
Bulevirtide with or without peginterferon alfa: real-world studies
P. Lampertico
Lonafarnib with or without peginterferon alpha/lambda
C. Yurdaydin
Anti-HBV drugs targeting HBsAg
F. Zoulim
Hot topics in HDV management.
Academia, Pharma and Diagnostics representatives
For Academia: S. Aleman, V. de Lédinghen, N. Reau, F. Zoulim
For Pharma and Diagnostics: M. Biermer, I. Choong, G. Cloherty, J.F. Flaherty, C. Hwang, A. Reinhardt, C. Simon
Closing remarks
P. Lampertico and H. Wedemeyer
Forgot password
Please enter your email address. You will receive a message with the link to reset your password.